Large-scale testing (Phase 3)Study completedNCT04350593What this trial is testingDapagliflozin in Respiratory Failure in Patients With COVID-19Who this might be right forCOVID-19 Saint Luke's Health System 1,250
Post-approval studies (Phase 4)Study completedNCT02700334What this trial is testingEffect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With PrediabetesWho this might be right forPrediabetesImpaired Fasting GlucoseImpaired Glucose Tolerance University of Guadalajara 24
Not applicableActive Not RecruitingNCT07198191What this trial is testingSGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort StudyWho this might be right forAcute Myocardial Infarction (AMI)Type 2 Diabetes Mellitus (T2DM) Yonsei University 200,000
Large-scale testing (Phase 3)Enrolling By InvitationNCT07065357What this trial is testingTreating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 InhibitorWho this might be right forMetabolic Syndrome The University of Hong Kong 160
Testing effectiveness (Phase 2)Active Not RecruitingNCT06111768What this trial is testingSodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility StudyWho this might be right forCardiorenal Syndrome Yale University 30
Not applicableStudy completedNCT07269197What this trial is testingAssociation of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 DiabetesWho this might be right forNon-Alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2 Josip Juraj Strossmayer University of Osijek 67
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06655480What this trial is testingTriple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEFWho this might be right forHFpEFLVDDMyocardial Fibrosis National Medical Research Center for Cardiology, Ministry of Health of Russian Federation 50
Large-scale testing (Phase 3)UnknownNCT05310916What this trial is testingEffect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus PatientsWho this might be right forDiabetic Retinopathy Nidae Alaa 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07273838What this trial is testingSodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal SyndromeWho this might be right forHeart FailureAcute Kidney Injury Yale University 130
Very early researchLooking for participantsNCT06430684What this trial is testingFeasibility Trial of Sodium-GLucose CoTransporter 2 INhibitors in Pediatric Chronic KIDney DiSeaseWho this might be right forChronic Kidney DiseasesPediatric Kidney Disease Ann & Robert H Lurie Children's Hospital of Chicago 40
Testing effectiveness (Phase 2)Study completedNCT03316131What this trial is testingAssess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UAWho this might be right forAsymptomatic Hyperuricemia AstraZeneca 36
Large-scale testing (Phase 3)WithdrawnNCT06560333What this trial is testingISGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)Who this might be right forDiabetes Mellitus, Type 2 Eurofarma Laboratorios S.A.
Post-approval studies (Phase 4)Active Not RecruitingNCT05590143What this trial is testingProMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2Who this might be right forAcute Kidney InjuryCardiac SurgerySodium-Glucose Transporter 2 Inhibitor Amsterdam UMC 784
Testing effectiveness (Phase 2)Looking for participantsNCT06483074What this trial is testingEmpagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis PatientsWho this might be right forEnd Stage Renal Disease on DialysisPeritoneal Dialysis ComplicationSodium-glucose Cotransporter-2 Inhibitor+1 more Chinese University of Hong Kong 48
Not applicableUnknownNCT05686616What this trial is testingSGLT2 Inhibitor for Severe Tricuspid RegurgitationWho this might be right forTricuspid Regurgitation Samsung Medical Center 72
Post-approval studies (Phase 4)Study completedNCT05989503What this trial is testingInitiation of ARNi and SGLT2i in Patients With HFrEFWho this might be right forHeart Failure With Reduced Ejection Fraction Universidade do Porto 62
Early research (Phase 1)Not Yet RecruitingNCT07172971What this trial is testingSodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne CardiomyopathyWho this might be right forDuchenne Muscular Dystrophy (DMD) Larry W. Markham 10
Post-approval studies (Phase 4)Study completedNCT06825156What this trial is testingMetabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 InhibitorsWho this might be right forAcute Kidney Injury Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 60
Testing effectiveness (Phase 2)Study completedNCT06150924What this trial is testingEfficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With AlbuminuriaWho this might be right forChronic Kidney Disease Mineralys Therapeutics Inc. 60
Large-scale testing (Phase 3)WithdrawnNCT07057479What this trial is testingPhase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on MetforminWho this might be right forType 2 Diabetes Mellitus (T2DM) Eurofarma Laboratorios S.A.